RT @Helios_Movement: Bonus number 15: Baby aspirin with vitamin K Now, aspirin can be a good tool. Just make sure that your gut is fine, p…
Bonus number 15: Baby aspirin with vitamin K Now, aspirin can be a good tool. Just make sure that your gut is fine, pair it with vitamin K and disolve it in a glass of water in order to not consume the additives that irritate the gut. https://t.co/uUWw0U
@lostinayr @Jackson90771 @jollycyanide @jakescottMD Read this and get back to me, moron. Or don't. https://t.co/2JdzmeeTre
@drabbyphilips https://t.co/wmjURShBsB The metanalyses says Aspirin is not effective in preventing cardiovascular events. Still it is the first drug of choice because one of the Ecosprin sales rep has come up with an amazing study which shows some fancy AR
@katarina_katja2 @NorwayLagherta @NavadniNimda @NovakBozidar @Kraljica00 Ja. Aspirin zmanjša verjetnost srčnega napada za 14% ampak hkrati pa poveča verjetnost notranjih krvavitev za 46%. Na koncu dneva naredi več škode kot koristi. https://t.co/D1z8YalM79
@josebas85 @elmundoes Que sea el tratamiento básico de pacientes de "riesgo" dice mucho del (poco) nivel científico de nuestros médicos https://t.co/53upeLeC59 Los riesgos protrombóticos del embarazo superan los de los anticonceptivos https://t.co/EkbHo5KK
@CRYPT0N1TE @drandyphung You can read the evidence on aspirin - there’s no need to speculate. https://t.co/pPgwHj0z1h
Tres subgrupos de pacientes: no fumadores, pacientes tratados con estatinas y hombres, tuvieron la mayor reducción de riesgo de MACE (Compuesto de los principales eventos cardiovasculares adversos). Para mayor información visita: https://t.co/nCLA12AAAE
Did you know that taking Aspirin can reduce your risk of having a major adverse cardiovascular event, heart attack and Ischemic stroke? But with that comes the increased risk of major bleeding due to Aspirins blood thinning #biom4180 https://t.co/UDPC3X6e3
RT @KardiologieWien: A new meta-analysis by a research group of @JSillerMatula from @MedUni_Wien shows that aspirin in primary prevention h…
RT @KardiologieWien: A new meta-analysis by a research group of @JSillerMatula from @MedUni_Wien shows that aspirin in primary prevention h…
RT @KardiologieWien: A new meta-analysis by a research group of @JSillerMatula from @MedUni_Wien shows that aspirin in primary prevention h…
RT @KardiologieWien: A new meta-analysis by a research group of @JSillerMatula from @MedUni_Wien shows that aspirin in primary prevention h…
A new meta-analysis by a research group of @JSillerMatula from @MedUni_Wien shows that aspirin in primary prevention has a heterogeneous effect with the greatest benefit in: - #nonsmokers, - #statin users, - and #males https://t.co/L6j2wYD9hV @BMCMedici
Usage of #Asprin in cardiology....#DiabetesAndAsprin https://t.co/ViYt6w0gMh
Para leer con 🔍. ASA en prevención primaria 2 metanalysis , recomiendo lectura de consideraciones clínicas JAMA 👉https://t.co/CvDCA0zzGY 👉https://t.co/0k8FnKuxUJ Consideraciones clínicas 👉https://t.co/67oIEUTLDS https://t.co/yRRoDKH25v
RT @JSillerMatula: If primary #prevention is a goal, than all aspects should be properly adressed: statins, smoking prevention, physical ac…
If primary #prevention is a goal, than all aspects should be properly adressed: statins, smoking prevention, physical activity and aspirin. Aspirin for primary prevention does not reduce MACE in smokers and in those without statins. @BMCMedicine https://
Aspirin use does not reduce all-cause or cardiovascular mortality and results in an insufficient benefit-risk ratio for CVD primary prevention. Non-smokers, patients treated with statins, and males had the greatest risk reduction of MACE across subgroups.
男性はよくわかりませんが、非喫煙者、スタチン治療患者ということで、心血管疾患のリスクが低い方がアスピリンは効果的?
RT @JSillerMatula: #Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three sub…
【メタアナリシス】サブグループに特に焦点をあてた心血管疾患の一次予防としてのアスピリン(非喫煙者、スタチン治療患者、男性はアスピリンによる主要心血管イベントの相対リスク減少が大きかった。) https://t.co/yX3Xe1rJEu
RT @JSillerMatula: #Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three sub…
RT @JSillerMatula: #Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three sub…
RT @JSillerMatula: #Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three sub…
RT @JSillerMatula: #Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three sub…
RT @JSillerMatula: #Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three sub…
RT @BMCMedicine: NEW research: #Aspirin for primary prevention of #cardiovascular disease: a meta-analysis with a particular focus on subgr…
RT @JSillerMatula: #Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three sub…
RT @JSillerMatula: #Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three sub…
RT @JSillerMatula: #Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three sub…
RT @BMCMedicine: NEW research: #Aspirin for primary prevention of #cardiovascular disease: a meta-analysis with a particular focus on subgr…
#Aspirin use for primary prevention did not translate into a net clinical benefit adjusted for mortality risk. Three subgroups had the greatest risk reduction of MACE: non-smokers, patients treated with #statins, and male #patients @CHengstenbergMD #cardio
"Aspirin use does not reduce all-cause or cardiovascular mortality + results in an insufficient benefit-risk ratio for CVD primary prevention. Non-smokers, patients treated with statins, and males had the greatest risk reduction of MACE across subgroups."
RT @BMCMedicine: NEW research: #Aspirin for primary prevention of #cardiovascular disease: a meta-analysis with a particular focus on subgr…
NEW research: #Aspirin for primary prevention of #cardiovascular disease: a meta-analysis with a particular focus on subgroups. @MedUni_Wien @PUMS_tweets @Oslounivsykehus https://t.co/XeFFnpd3LV https://t.co/HptWzC7D2D